News | September 23, 2008

Bracco, Lantheus Partner to Promote CardioGen 82 for PET Perfusion Imaging

September 24, 2008 - Bracco Diagnostics Inc. and Lantheus Medical Imaging Inc. said yesterday they entered into an agreement for Lantheus to co-promote Bracco’s CardioGen-82 (Rubidium Rb 82 Generator), a myocardial perfusion positron emission tomography (PET) imaging agent.

CardioGen-82 is the only generator-based PET perfusion agent approved by the FDA and reimbursed for the evaluation of coronary artery disease (CAD).

CardioGen-82 was approved by the FDA in 1989 and has been used in hundreds of thousands of patients since then. CardioGen-82 PET myocardial perfusion imaging (MPI) has experienced double digit year-over-year growth since 2003. The companies said the agreement will further accelerate the rapid expansion of this modality.

“In seeking a partner to help us maximize the availability of CardioGen-82 to physicians whose patients may benefit from this PET imaging agent, we sought a company with vast experience in the myocardial perfusion imaging market and an extensive and knowledgeable sales force,” said Carlo Medici, president and CEO of Bracco Diagnostics Inc. “Lantheus Medical Imaging stood out as a company extremely well-suited for a partnership of this kind and we expect that this collaboration will quickly increase access to CardioGen-82.”

For more information: www.lantheus.com

Related Content

PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
News | Business | September 19, 2017
September 19, 2017 — Invicro LLC, a provider of imaging services and software for research and drug development, anno
Overlay Init